No decision on Indian drug price control without pharma industry discussions, says minister

10 March 2016

The Indian government will not take any decision on drug price control without holding discussions with the pharmaceutical industry and other stakeholders, Union Minister of State for Chemicals and Fertilisers, Hansraj Gangaram Ahir, said at an ASSOCHAM (The Associated Chambers of Commerce & Industry of India) event held in New Delhi today.

“We take every step very carefully when it comes to the issue of drug price control as we do not want to take even a single step without holding discussions with the industry,” said Mr Ahir, while inaugurating ‘MEDCON 2016,’ organized by the ASSOCHAM.

He said that government wants the prices of medicines to be affordable for general public, but at the same it wants the industry to flourish, noting: “We need to promote the industry for sure, this is certain.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK